Arcoxia review in May?
Executive Summary
Merck's COX-2 inhibitor Arcoxia (etoricoxib) may go before FDA's Arthritis Advisory Committee in mid-May. The committee is set to meet May 14-15, although an agenda has not been announced. Merck submitted an NDA for Arcoxia in October, including data suggesting a cardiovascular event profile similar to that seen with Vioxx (rofecoxib) ("The Pink Sheet" Dec. 17, p. 12)...